Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Compugen (CGEN) stocks in Canada

Learn how to easily invest in Compugen stocks.

Compugen is a biotechnology business based in the US. Compugen stocks (CGEN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.15 – a decrease of 5.77% over the previous week. Compugen employs 68 staff and has a trailing 12-month revenue of around $8 million.

How to buy shares in Compugen

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compugen stock price (NASDAQ:CGEN)

Use our graph to track the performance of CGEN stocks over time.

Compugen shares at a glance

Information last updated 2022-01-24.
Latest market close$3.59
52-week range$3.29 - $14.17
50-day moving average $4.48
200-day moving average $6.50
Wall St. target price$20.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.41

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Compugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Compugen price performance over time

Historical closes compared with the close of $3.59 from 2022-01-25

1 week (2022-01-19) -5.77%
1 month (2021-12-27) -18.22%
3 months (2021-10-27) -41.34%
6 months (2021-07-27) -43.73%
1 year (2021-01-27) -68.62%
2 years (2020-01-24) -45.61%
3 years (2019-01-25) 3.64
5 years (2017-01-26) 4.7

Compugen financials

Revenue TTM $8 million
Gross profit TTM $1.9 million
Return on assets TTM -16.71%
Return on equity TTM -30.19%
Profit margin 0%
Book value $1.18
Market capitalisation $321.1 million

TTM: trailing 12 months

Compugen share dividends

We're not expecting Compugen to pay a dividend over the next 12 months.

Compugen share price volatility

Over the last 12 months, Compugen's shares have ranged in value from as little as $3.29 up to $14.17. A popular way to gauge a stock's volatility is its "beta".

CGEN.US volatility(beta: 2.31)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compugen's is 2.3142. This would suggest that Compugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Compugen overview

Compugen Ltd. , a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site